Acquisition by Megna Michael R of 175 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3

KNSA Stock  USD 19.88  0.78  3.78%   
About 62% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Kiniksa Pharmaceuticals Officer Chief Accounting Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Kiniksa insider trading alert for acquisition of class a ordinary share by Megna Michael R, Officer: Chief Accounting Officer, on 3rd of November 2024. This event was filed by Kiniksa Pharmaceuticals with SEC on 2024-10-04. Statement of changes in beneficial ownership - SEC Form 4

Kiniksa Pharmaceuticals Fundamental Analysis

We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Kiniksa Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Kiniksa Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Kiniksa Pharmaceuticals Related Equities

CHRSCoherus BioSciences   10.66   
0%
100.0%
COGTCogent Biosciences   3.44   
0%
32.0%
GOSSGossamer Bio   3.13   
0%
29.0%
REPLReplimune   2.64   
0%
24.0%
SPROSpero Therapeutics   1.16   
0%
10.0%
ACLXArcellx   0.81   
0%
7.0%
NVCTNuvectis Pharma   0.30   
0%
2.0%
GPCRStructure Therapeutics   1.15   
10.0%
0%
KURAKura Oncology   1.49   
13.0%
0%
KRONKronos Bio   1.94   
18.0%
0%
VTYXVentyx Biosciences   1.95   
18.0%
0%
BOLTBolt Biotherapeutics   2.00   
18.0%
0%
NUVLNuvalent   2.21   
20.0%
0%
LRMRLarimar Therapeutics   3.27   
30.0%
0%
DAWNDay One   3.81   
35.0%
0%
CGEMCullinan Oncology   3.83   
35.0%
0%
LYRALyra Therapeutics   5.26   
49.0%
0%
PHATPhathom Pharmaceuticals   5.52   
51.0%
0%

Complementary Tools for Kiniksa Stock analysis

When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Volatility Analysis
Get historical volatility and risk analysis based on latest market data